Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value (NASDAQ:KRYS)
· seekingalpha.com
Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Read more on KRYS stock here.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...